Free Trial

United Therapeutics (NASDAQ:UTHR) Stock Price Up 4.9% - Here's Why

United Therapeutics logo with Medical background

Key Points

  • United Therapeutics' stock rose by 4.9%, trading between $290.00 and $288.12, while the trading volume fell by 74% from its average.
  • Recent analyst ratings shifted, with Bank of America and Morgan Stanley lowering their price targets, while HC Wainwright issued a "buy" rating with a price target of $400.00.
  • United Therapeutics reported a quarterly earnings miss, with an EPS of $6.41 against an estimate of $6.80, despite a 11.7% increase in revenue year-over-year.
  • Five stocks we like better than United Therapeutics.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report)'s share price was up 4.9% on Friday . The stock traded as high as $290.00 and last traded at $288.12. Approximately 129,971 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 493,307 shares. The stock had previously closed at $274.70.

Analysts Set New Price Targets

Several analysts have weighed in on UTHR shares. Bank of America dropped their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Morgan Stanley dropped their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. Wells Fargo & Company dropped their target price on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research report on Thursday. Finally, HC Wainwright set a $400.00 target price on shares of United Therapeutics and gave the company a "buy" rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $379.69.

Check Out Our Latest Analysis on UTHR

United Therapeutics Stock Up 6.4%

The company's 50 day moving average price is $298.39 and its 200-day moving average price is $314.07. The stock has a market cap of $13.18 billion, a P/E ratio of 11.38, a P/E/G ratio of 6.15 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the business posted $5.85 EPS. United Therapeutics's revenue was up 11.7% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity

In related news, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 70,681 shares of company stock worth $21,318,359 over the last ninety days. Corporate insiders own 10.30% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares in the last quarter. Cerity Partners LLC increased its position in shares of United Therapeutics by 30.4% during the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares in the last quarter. Concurrent Investment Advisors LLC bought a new stake in shares of United Therapeutics during the first quarter worth about $227,000. Finally, Nepsis Inc. increased its position in shares of United Therapeutics by 6.7% during the first quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after acquiring an additional 3,653 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines